RecruitingNCT06663111

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)

Sponsor

Haukeland University Hospital

Enrollment

60 participants

Start Date

Mar 15, 2021

Study Type

OBSERVATIONAL

Conditions

Relapsing Remitting Multiple Sclerosis

Summary

ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria2

Included in OVERLORD-MS (NCT04578639)
Willing to attend laboratory for blood sample collection at scheduled time points

Exclusion Criteria1

\* Not willing to attend laboratory for blood sample collection at scheduled time points

Interventions

OTHERBlood samples for PK

Blood sampled for pharmacokinetic study

OTHERBlood samples for PK

Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.

Locations(1)

Haukeland University Hospital, Deparment of medical biochemistry and pharmacology

Bergen, Vestland, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06663111

Related Trials

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

NCT067965043 locations

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

NCT0575883123 locations

Functional Outcomes From Diets in Multiple Sclerosis

NCT053273222 locations

Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

NCT059495805 locations

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT0404762822 locations